// App-Quantinova.ai

: Safety and efficacy of six months' open label extension post-RCT using the novel cathepsin K inhibitor MIV-711 in patients with knee osteoarthritis

Researchers

Presenter

  • P.G. Conaghan

Principal Investigators

  • M.A. Bowes

  • S.R. Kingsbury

  • A. Brett

  • G. Guillard

  • K. Thunblad

  • T. Larsson

  • A Holmgren

  • A. Manninen

  • K. Gohlin

  • N. Sjogren

  • P. Graham

  • A Jansson

  • C. Wadell

  • R. Bethell

  • J. ahd

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Imorphics, Manchester, United Kingdom

  • Medivir AB, Huddinge, Sweden

Locations

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Knee osteoarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • MIV711

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved